Physician profile
Mark S Lee
NPI 1679515522
$8,084.42
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $1,608 · 2021: $1,629 · 2022: $1,515 · 2023: $1,800 · 2024: $29.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,829.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $973.93 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $804.55 | 2019-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $797.58 | 2019-2023 | Farxiga, Breztri |
| Abbvie INC. | $554.22 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.86 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $451.51 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $424.64 | 2019-2020 | |
| Abbott Laboratories | $367.70 | 2021-2023 | Freestyle Libre |
| Lilly USA, LLC | $363.79 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $347.08 | 2020-2023 | Xarelto |
| Pfizer INC. | $333.15 | 2019-2023 | |
| Amarin Pharma, INC. | $285.19 | 2019-2021 | |
| Astellas Pharma US INC | $262.51 | 2019-2023 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $217.61 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.76 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.